Just found my new favorite trial: the DECAF trial!!! Caffeinated Coffee Consumption or Abstinence to Reduce Atrial Fibrillation url: jamanetwork.com/journals/jam...

Metformin, the first line drug for Type 2 diabetes, has been used for 60 years without a clearcut mechanism of action. It turns out it's not just reducing glucose output from the liver. Metformin also works via the brain www.science.org/doi/10.1126/...

Multi-omic underpinnings of Alzheimer's disease promote inflammation (particularly via T cells)whereas those for stroke relate to vascular integrity @cp-neuron.bsky.social www.cell.com/neuron/abstr...

NEW content online!

Understanding and reversing mammary tumor-driven reprogramming of myelopoiesis to reduce metastatic spread: @cp-cancercell.bsky.social www.cell.com/cancer-cell/...

Interesting preprint on TCR-pMHC prediction and functional validation, with a great thread! 👇🏼 By the Shumacher Lab

Risk of Colorectal Cancer Associated With Frequency of Colorectal Polyp Diagnosis in Relatives - @gastroenterology.bsky.social www.gastrojournal.org/article/S001...

The US National Institutes of Health has terminated nearly 800 research projects at a breakneck pace, wiping out significant chunks of funding to entire scientific fields Read the full story: https://go.nature.com/3EuFRPV

For patients with IgG4-related disease, there are no approved therapies. Research findings on the efficacy and safety of inebilizumab ― a monoclonal antibody that targets and depletes CD19+ B-cells ― are summarized in a new Quick Take video. nej.md/421enZX #MedSky #RheumSky

🚨 New: Spleen-resident macrophages (MMMs) can directly activate CD8+ T cells to fight tumors – independently of dendritic cells. They use a vacuolar MHC-I pathway & need Batf3 for this antitumor response. 🧠 A game-changer for immunotherapy? 🔗 www.cell.com/immunity/abs... @cp-immunity.bsky.social

Or upfront ablation, when appropriate... ;)

Terrible indeed! Everyone should be supporting and advocating for MORE (not less) funding for research on such devastating diseases as Pancreatic Cancer, especially when their incidence is rising!... @pancan.bsky.social @pancreaticcanuk.bsky.social @pce-europe.bsky.social @letswinpc.bsky.social

Couldn't agree more with this. Precision dosing is the way. Max tolerated dose treatment by default, can detrimental for some patients, especially those that rely to a bigger extent on immune-mediated tumor control, and whose immune system is crippled by MTD chemo.

Kicking off an exciting Clinical Cancer Genomics 2025 conference with an overview of national molecular profiling strategies of 6 EU countries. Important points: -WGS provides prognostic info (not just actionable targets)! -Need to more data on various ancestries -Need to increase testing! #CCG2025

Learn more about the APAChE study: 📄 Read the full results published in NEJM: nej.md/3IrM6T8 📄 Read the editorial by Philip J. Landrigan, MD: nej.md/48CvGSs 📺 Watch the interview with Dr. Landrigan: nej.md/41SCs6f

Nice summary video by @nejm.org on the INSEMA trial 👉In T1/small T2 breast cancers with clinically negative axilla, omitting SLN Biopsy is non-inferior to performing it: ✅ est. 5y inv.DFS of 92% at 6 years median f/up ✅ signif. less lymphedema & arm pain/restriction www.nejm.org/do/10.1056/N...

👇 Not promising at all... 😣 Chemical industry lobbyists will run chemical safety oversight at US EPA - The Lancet Oncology www.thelancet.com/journals/lan...

This is consistent with our 2021 @annsurgoncology.bsky.social paper on resectable PDAC showing better OS after metachronous Extrahepatic-only recurrence, vs Liver recur: link.springer.com/article/10.1... 👉 PDAC #organotropism informs on tumor biologic aggressiveness. @metastasisresearch.bsky.social

Miriam Merad & Co ‪@sinaiimmuno.bsky.social‬ outline the molecular basis of #DendriticCell maturation and the mechanisms through which cancer impairs #DC maturation and consider the potential for DC-focused cancer #immunotherapeutics. 📖 ⬇️

In case you missed our live event covering the latest in #pancreaticcancer clinical trials, you can watch the full recording now at pancan.org/clinicaltrials2025 🔬💜 Learn from experts about the basics of clinical trials, what developments are on the horizon and how to find the right trial for you.

Amazing story! www.kathimerini.gr/society/5634...

Ok let's see what this platform has to offer, given X's decline... :)